ERBB2 and breast cancer: In recent years, four intrinsic biological subtypes of breast cancer including luminal A, luminal B, HER2-enriched and basal-like have been revealed by comprehensive transcriptional profiling studies and have been shown to be robust for predicting treatment sensitivity and survival outcomes [23, 28].